A 2025 systematic review and meta analysis, which essentially compiles and examines existing studies as a whole to draw broad conclusions, does not regard tirzepatide as superior to semaglutide for chronic weight management
Compared to semaglutide (Ozempic, Wegovy), retatrutide produces more GI side effects at doses that achieve equivalent or greater weight loss
Cigna may also provide coverage based on medical necessity proof, while Blue Cross Blue Shield's coverage differs across states
For patients where cardiovascular protection is the primary concern, both are reasonable choices, though semaglutides data may suggest greater benefit
References: Yakar, S et al., 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton (Jul 2018)
The potential federal and state budgetary impacts of expanded coverage of GLP-1s for obesity in Medicare and Medicaid are unknown CMS documentation does not include potential federal or state budgetary impacts from either the BALANCE Model or the Medicare GLP-1 Bridge